Lantern Pharma Inc Ordinary Shares LTRN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
New to The Street Show 775 Premieres Tonight on Bloomberg Television Across the United States, Latin America, MENA and Southeast Asia, Featuring American Fusion, HPB, T-REX Acquisition Corp. and SyncMeOn
-
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 15th, 2026
-
Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC
-
Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering
-
Lantern Pharma Inc. Announces up to $8 Million Registered Direct Offering
-
New to The Street Show 773 Premieres Tonight on Bloomberg Television, Featuring Glint, Sagtec Global, BioVie and SafeSpace Global
-
Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET
-
Lantern Pharma Secures USPTO Notice of Allowance for LP‑284 Treatment Patent in Aggressive B‑Cell Lymphomas
Trading Information
- Previous Close Price
- $0.83
- Day Range
- $0.76–0.83
- 52-Week Range
- $0.76–4.68
- Bid/Ask
- $0.83 / $0.83
- Shares Outstanding
- 14.94M
- Market Cap
- $12.14M
- Volume/Avg
- 274,877 / 184,501
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 16
- Website
- https://www.lanternpharma.com
Valuation
|
Metric
|
LTRN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
LTRN
|
|---|---|
Quick Ratio | 1.70 |
Current Ratio | 1.96 |
Interest Coverage | — |
Quick Ratio
LTRN
Profitability
|
Metric
|
LTRN
|
|---|---|
Return on Assets (Normalized) | −153.83% |
Return on Equity (Normalized) | −308.53% |
Return on Invested Capital (Normalized) | −308.34% |
Return on Assets
LTRN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|hLxFH#D | LOCK|Yt%Cq | $129B | |||
| Moderna Inc
MRNA
| LOCK|#QFd#% | LOCK|!Q | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|Ck?$@@l | LOCK|<Mrk | $77B | |||
| argenx SE ADR
ARGX
| LOCK|#?yzFK | LOCK|KP< | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|$MS^<&@ | LOCK|CLs | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|&Y^J?wx | LOCK|>Gr< | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|R^HK%?Xx | LOCK|$#^$? | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|#X!>!c | LOCK|$%C | $24B | |||
| Incyte Corp
INCY
| LOCK|gDsd!Z | LOCK|<WW | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|^t%z!g | LOCK|?T | $14B |
United States